Neuroleptic Malignant Syndrome: A Review from a Clinically Oriented Perspective
Open accessThe DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Abstract
Neuroleptic malignant syndrome (NMS) is a rare but potentially life-threatening side-effect that can occur in response to treatment with antipsychotic drugs. Symptoms commonly include hyperpyrexia, muscle rigidity, autonomic dysfunction and altered mental status. In the current review we provide an overview on past and current developments in understanding the causes and treatment of NMS. Studies on the epidemiological incidence of NMS are evaluated, and we provide new data from the Canada Vigilance Adverse Reaction Online database to elaborate on drug-specific and antipsychotic drug polypharmacy instances of NMS reported between 1965 and 2012. Established risk factors are summarized with an emphasis on pharmacological and environmental causes. Leading theories about the etiopathology of NMS are discussed, including the potential contribution of the impact of dopamine receptor blockade and musculoskeletal fiber toxicity. A clinical perspective is provided whereby the clinical presentation and phenomenology of NMS is detailed, while the diagnosis of NMS and its differential is expounded. Current therapeutic strategies are outlined and the role for both pharmacological and non-pharmacological treatment strategies in alleviating the symptoms of NMS are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Patients with a previous history of NMS and/or a personal or family history of catatonia are also at higher risk.867”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS, FIFTH EDITION
Abbas, A., & Aminoroaia, M. (2013) · Cited by 1,479
Dunkley, E. J. C., Isbister, G. K., Sibbritt, D., Dawson, A. H., & Whyte, I. M. (2003) · QJM · doi:10.1093/qjmed/hcg109 · Cited by 1,029 · cited 1×
“Serotonin syndrome is a condition characterized by the presence of changes in mental status, agitation, clonus, hyperreflexia, and hyperthermia as a result of toxic and excessive serotoninergic stimulation [60].”
BackgroundNeuroleptic malignant syndrome
(1985) · American Journal of Psychiatry · doi:10.1176/ajp.142.10.1137 · Cited by 978
Serotonin receptors : their key role in drugs to treat schizophrenia
Meltzer, H. Y., Li, Z., Kaneda, Y., & Ichikawa, J. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2003.09.010 · Cited by 775 · cited 1×
“a more balanced dopamine D2 and 5-HT receptor blockade, particularly at the 5-HT2A receptor [26]), the evidence from the current literature is not conclusive in either direction [24].”
BackgroundCatatonia in Psychiatric Classification: A Home of Its Own
Taylor, M. A., & Fink, M. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.7.1233 · Cited by 581 · cited 1×
“ECT), and that NMS-like presentations are well documented before the development of antipsychotics [67].”
BackgroundNeuroleptic malignant syndrome
Caroff, S. N., & Mann, S. C. (1993) · Medical Clinics of North America · doi:10.1016/s0025-7125(16)30278-4 · Cited by 514
Neuroleptic malignant syndrome: A pathogenetic role for dopamine receptor blockade?
Henderson, V. W., & Wooten, G. F. (1981) · Neurology · doi:10.1212/wnl.31.2.132 · Cited by 339
Prevention of Ventilator-Associated Pneumonia: An Evidence-Based Systematic Review
Collard, H. R., Saint, S., & Matthay, M. A. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-6-200303180-00015 · Cited by 304
Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital
(1986) · American Journal of Psychiatry · doi:10.1176/ajp.143.10.1227 · Cited by 302 · cited 4×
“15%, which was comparatively lower than the rate reported by Pope and colleagues five years earlier [4].”
BackgroundResultInfluentialMortality from neuroleptic malignant syndrome.
Shalev, A. Y., Hermesh, H., & Munitz, H. (1989) · PubMed · Cited by 290
Cited by
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., et al. (2018) · Bipolar Disorders · doi:10.1111/bdi.12609 · Cited by 1,852
Galletly, C., Castle, D., Dark, F., Humberstone, V., Jablensky, A., Killackey, E., Kulkarni, J., McGorry, P., Nielssen, O., & Tran, N. (2016) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867416641195 · Cited by 877
“Neuroleptic malignant syndrome (NMS) is a rare and potentially life-threatening condition characterised by fever, rigidity, tremor, sympathetic nervous system dysregulation and creatine kinase (CK) elevation (Tse et al., 2015).”
BackgroundBarnes, T. R., Drake, R., Paton, C., Cooper, S. J., Deakin, B., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I., et al. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 606
Management of common adverse effects of antipsychotic medications
Stroup, T. S., & Gray, N. (2018) · World Psychiatry · doi:10.1002/wps.20567 · Cited by 572
Solmi, M., Murru, A., Pacchiarotti, I., Undurraga, J., Veronese, N., Fornaro, M., Stubbs, B., Monaco, F., Vieta, E., Seeman, M., et al. (2017) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s117321 · Cited by 438
“medical comorbidities, previous history of NMS, family history of catatonia, and muscle channelopathy.(230)”
Influential
Metadata
- Authors
- Tse, L., Barr, A., Scarapicchia, V., & Vila-Rodriguez, F.
- Affiliations
- University of British Columbia Hospital (CA)
- University of British Columbia (CA)
- ORCID
- Barr, Alasdair
- Venue
- Current Neuropharmacology
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2015-07-14
- Volume
- 13
- Issue
- 3
- Pages
- 395-406
- ISSN
- 1570-159X (ISSN-L)
- PMC
- PMC4812801
- OpenAlex
- W2332600596
- Cited by
- 179
- References
- 73
- Citations by year
- 2026: 7 · 2025: 18 · 2024: 25 · 2023: 26 · 2022: 15 · 2021: 27 · 2020: 11 · 2019: 16 · 2018: 19 · 2017: 4 · 2016: 10 · 2015: 1
- FWCI
- 9.19
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- cc-by-nc
- Locations
- Current Neuropharmacology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- neuroleptic malignant syndrome, antipsychotic adverse effects, hyperpyrexia, muscle rigidity, autonomic dysfunction, altered mental status, adverse drug reaction reporting, risk factors, dopamine receptor blockade, etiopathogenesis, diagnosis, differential diagnosis, treatment options, polypharmacy
- MeSH terms
- Animals, Diagnosis, Differential, Humans, Muscle Rigidity, Neuroleptic Malignant Syndrome, Risk Factors, Antipsychotic Agents, Incidence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neuroleptic Malignant Syndrome: A Review from a Clinically Oriented Perspective. https://app.cochat.ai/papers/10.2174/1570159x13999150424113345
- The paper
- Tse, L., Barr, A., Scarapicchia, V., & Vila-Rodriguez, F. (2015). Neuroleptic Malignant Syndrome: A Review from a Clinically Oriented Perspective. Current Neuropharmacology. https://doi.org/10.2174/1570159x13999150424113345
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.